Search Results for "vol"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for vol. Results 541 to 550 of 1447 total matches.
Ixekizumab (Taltz) - A Second IL-17A Inhibitor for Psoriasis
The Medical Letter on Drugs and Therapeutics • May 09, 2016 (Issue 1494)
. Patients received etanercept 50 mg twice weekly.
60
The Medical Letter ® Vol. 58 (1494) May 9, 2016 ...
The FDA has approved ixekizumab (Taltz – Lilly), an
injectable humanized interleukin (IL)-17A antagonist,
for treatment of adults with moderate to severe plaque
psoriasis who are candidates for systemic therapy
or phototherapy. Ixekizumab is the second IL-17A
antagonist to be approved for this indication in the US;
secukinumab (Cosentyx – Novartis) was the first.
BioThrax and Anthrasil for Anthrax
The Medical Letter on Drugs and Therapeutics • May 09, 2016 (Issue 1494)
that
received antibiotics alone.
63
The Medical Letter ® Vol. 58 (1494) May 9, 2016
1. JG Wright et al. Use ...
The FDA has approved anthrax vaccine adsorbed (AVA;
BioThrax – Emergent BioSolutions) for prevention of
anthrax disease in adults following exposure to Bacillus
anthracis and intravenous anthrax immune globulin
(Anthrasil – Emergent BioSolutions) for treatment of
inhalation anthrax in adults and children. AVA has been
available since 1970 for prevention of anthrax disease
in persons at high risk of exposure.
Odefsey - Another NNRTI Combination for HIV
The Medical Letter on Drugs and Therapeutics • May 09, 2016 (Issue 1494)
antagonists at least 12 hours
before or 4 hours after the combination.
61
The Medical Letter ® Vol. 58 ...
The FDA has approved Odefsey (Gilead), a once-daily,
fixed-dose combination of the non-nucleoside
reverse transcriptase inhibitor (NNRTI) rilpivirine
and the nucleoside/nucleotide reverse transcriptase
inhibitors (NRTIs) emtricitabine and tenofovir
alafenamide, for initial treatment of HIV-1 infection in
patients with HIV-1 RNA (viral load) ≤100,000 copies/mL or to replace a stable antiretroviral regimen in
patients who have been virologically suppressed
(viral load <50 copies/mL) for at least six months with
no history of treatment failure.
In Brief: Two Drugs for Soft-Tissue Sarcoma (online only)
The Medical Letter on Drugs and Therapeutics • May 09, 2016 (Issue 1494)
Letter ® Vol. 58 (1494) May 9, 2016
PRESIDENT: Mark Abramowicz, M.D.; VICE PRESIDENT AND EXECUTIVE ...
The anthracycline doxorubicin with or without the alkylating agent ifosfamide is the standard first-line treatment for advanced soft-tissue sarcomas. The FDA recently approved the minor groove DNA intercalator trabectedin (Yondelis – Janssen) for treatment of unresectable or metastatic liposarcoma or leiomyosarcoma in patients previously treated with an anthracycline. Trabectedin has been available for years in Europe for treatment of advanced soft-tissue sarcoma. The FDA has also approved the microtubule inhibitor eribulin mesylate (Halaven – Eisai), which was approved earlier for...
Cariprazine (Vraylar) for Schizophrenia and Bipolar I Disorder
The Medical Letter on Drugs and Therapeutics • Apr 25, 2016 (Issue 1493)
:63.
10. GS Sachs et al. J Affect Disord 2015; 174:296.
52
The Medical Letter ® Vol. 58 (1493 ...
The FDA has approved cariprazine (Vraylar – Actavis), an
oral, once-daily, second-generation antipsychotic, for treatment
of schizophrenia and for acute treatment of manic or
mixed episodes associated with bipolar I disorder.
Buprenorphine Buccal Film (Belbuca) for Chronic Pain
The Medical Letter on Drugs and Therapeutics • Apr 11, 2016 (Issue 1492)
The Medical Letter ® Vol. 58 (1492) April 11, 2016
Excess sedation and respiratory depression may also
occur ...
Belbuca (Endo), a buccal formulation of the partial
opioid agonist buprenorphine, has been approved by the
FDA for management of pain severe enough to require
daily, around-the-clock, long-term opioid treatment.
Buprenorphine is also available as a transdermal patch
(Butrans) and in a parenteral formulation (Buprenex, and
generics) for treatment of pain. A sublingual formulation
of buprenorphine and buccal and sublingual formulations
containing buprenorphine and the opioid antagonist
naloxone are approved for use as alternatives to
methadone for treatment of opioid...
Dichlorphenamide (Keveyis) for Periodic Paralysis
The Medical Letter on Drugs and Therapeutics • Apr 11, 2016 (Issue 1492)
Letter ® Vol. 58 (1492) April 11, 2016
1. E Matthews et al. Acetazolamide efficacy in hypokalemic ...
Dichlorphenamide (Keveyis – Taro), an oral carbonic
anhydrase inhibitor, has been approved by the
FDA for treatment of primary hypokalemic and
hyperkalemic periodic paralysis and related variants.
Dichlorphenamide is the first drug to be approved in
the US for this indication. It was approved as Daranide
in 1958 for treatment of glaucoma, but had not been
marketed since 2002.
Seebri Neohaler and Utibron Neohaler for COPD
The Medical Letter on Drugs and Therapeutics • Mar 28, 2016 (Issue 1491)
The Medical Letter ® Vol. 58 (1491) March 28, 2016
significantly more than glycopyrrolate or indacaterol ...
The FDA has approved two new inhalers for long-term
maintenance treatment of chronic obstructive
pulmonary disease (COPD). Seebri Neohaler
(Novartis) contains the long-acting anticholinergic
glycopyrrolate. Utibron Neohaler (Novartis) contains
both glycopyrrolate and the long-acting beta2-adrenergic agonist (LABA) indacaterol. Glycopyrrolate/indacaterol is the third fixed-dose combination of a
long-acting anticholinergic and a LABA to become
available in the US; umeclidinium/vilanterol (Anoro
Ellipta) and tiotropium/olodaterol (Stiolto Respimat)
were approved...
Lumacaftor/Ivacaftor (Orkambi) for Cystic Fibrosis
The Medical Letter on Drugs and Therapeutics • Mar 28, 2016 (Issue 1491)
) that
42
The Medical Letter ® Vol. 58 (1491) March 28, 2016
serum concentrations and efficacy of the many ...
The FDA has approved a fixed-dose combination
of lumacaftor and ivacaftor (Orkambi – Vertex) for
oral treatment of cystic fibrosis (CF) in patients
≥12 years old who are homozygous for the F508del
mutation. About 50% of patients in the US with
CF are homozygous for the F508del (also called
Phe508del) mutation. This is the first approved
indication for lumacaftor; ivacaftor is available
alone as Kalydeco for treatment of CF in patients
≥2 years old with other mutations. Orkambi is the
first drug to be approved in the US for treatment of
patients with the F508del...
Cobimetinib (Cotellic) for Metastatic Melanoma
The Medical Letter on Drugs and Therapeutics • Mar 28, 2016 (Issue 1491)
Med 2014; 371:1867.
44
The Medical Letter ® Vol. 58 (1491) March 28, 2016
DOSAGE — Cobimetinib ...
The FDA has approved the mitogen-activated
extracellular signal-regulated kinase (MEK) inhibitor
cobimetinib (Cotellic – Genentech) for use in combination
with the BRAF kinase inhibitor vemurafenib
(Zelboraf) for treatment of unresectable or metastatic
melanoma with a BRAF V600E or V600K mutation.